Plus Therapeutics (NASDAQ:PSTV) Price Target Lowered to $4.00 at D. Boral Capital

Plus Therapeutics (NASDAQ:PSTV) had its target price reduced by D. Boral Capital from $5.00 to $4.00 in a research note issued to investors on Thursday morning,Benzinga reports. They currently have a buy rating on the stock.

PSTV has been the topic of a number of other research reports. Zacks Research downgraded shares of Plus Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, November 11th. HC Wainwright restated a “buy” rating and set a $2.00 target price on shares of Plus Therapeutics in a research report on Wednesday, November 26th. Ascendiant Capital Markets lowered their price target on shares of Plus Therapeutics from $21.00 to $19.00 and set a “buy” rating for the company in a report on Friday, November 21st. Finally, Weiss Ratings reiterated a “sell (e+)” rating on shares of Plus Therapeutics in a research report on Wednesday, October 8th. One analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, Plus Therapeutics has a consensus rating of “Moderate Buy” and an average price target of $7.00.

Plus Therapeutics Trading Down 2.3%

Shares of Plus Therapeutics stock opened at $0.29 on Thursday. The stock has a 50 day moving average of $0.53 and a 200 day moving average of $0.54. Plus Therapeutics has a 12 month low of $0.16 and a 12 month high of $2.31. The firm has a market cap of $39.59 million, a PE ratio of -0.15 and a beta of 0.85.

Plus Therapeutics (NASDAQ:PSTV) last released its quarterly earnings data on Thursday, October 30th. The company reported ($0.04) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.02) by ($0.02). The business had revenue of $1.40 million during the quarter, compared to analyst estimates of $1.50 million. As a group, equities research analysts forecast that Plus Therapeutics will post -2.3 earnings per share for the current fiscal year.

Institutional Trading of Plus Therapeutics

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Jane Street Group LLC purchased a new position in shares of Plus Therapeutics during the second quarter valued at approximately $41,000. Susquehanna International Group LLP bought a new stake in shares of Plus Therapeutics during the 3rd quarter worth approximately $46,000. Scientech Research LLC purchased a new position in Plus Therapeutics during the 3rd quarter valued at $100,000. Finally, Altium Capital Management LLC bought a new position in Plus Therapeutics in the 3rd quarter valued at $628,000. 3.28% of the stock is owned by hedge funds and other institutional investors.

About Plus Therapeutics

Plus Therapeutics is a clinical‐stage biopharmaceutical company specializing in the development of targeted radiotherapeutics for oncology. Its platform technologies leverage nanoliposomes and microspheres to deliver therapeutic radioisotopes directly to tumor sites. The company’s lead candidate, 90Y-HP-DO3A, is in Phase 2 development for recurrent high-grade gliomas, while its rhenium-based nanoliposome program is under investigation for diffuse intrinsic pontine glioma and brain metastases.

The pipeline also includes investigational treatments for bone metastases, malignant pleural effusions and other hard-to-treat solid tumors.